FluoroPhama (FPMI) is developing pioneering molecular imaging agents for Positron Emission Tomography (PET) as a response to critical medical problems. As well, the company is making strides in “the discovery, development and commercialization of proprietary medical diagnostic imaging products.” Other products FluoroPhama is working on are: the development of a device to identify inflamed atherosclerotic plaque in peripheral arteries as well as certain types of cancer; amyloid plaque in Alzheimer’s disease.
Related Links:
Boyan Goumnerov
Tamara Rhein